Medacta Group Sa · SIX:MOVE
Medacta Group Sa — H1 2021 Earnings Presentation
21 slides from Medacta Group Sa's earnings presentation, Sep 10, 2021
Slide 1: 1H 2021 Financial Results
1H 2021 Financial Results 10 September 2021
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on ou
Slide 3: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer 1H 2021 Financial Results
Slide 4: 1H 2021 Highlights
1H 2021 Highlights* * Alternative Performance Measures: This presentation contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency", "EBITDA", "Adjusted EBITDA" or “CORE EBITDA”, "Free Cash Flow", “Adjusted Free Cash Flow”, “
Slide 5: 1H 2021 Highlights
1H 2021 Highlights 1H 2021 revenue increased to Euro 177.5 million, or 35.4% at constant currency (31.7% reported) vs 1H 2020 thanks to a significant carry-over and customer acquisition, in addition to normalization of surgery activities, with positive contributions from all business lines and geo
Slide 6: Deployment of the NextAR AR Surgical Platform
Deployment of the NextAR™ AR Surgical Platform In June 2021, the first surgeries based on our NextAR Augmented Reality (AR) Surgical Platform were performed in Europe, following the CE-marking of the Knee, Shoulder and Spine Applications Also, in May 2021, the NextAR Shoulder Application receive
Slide 7: Corrado Farsetta, Chief Financial Officer
CORRADO FARSETTA Chief Financial Officer 1H 2021 Financial Results
Slide 8: 1H 2021 Revenue Bridge by Product Line
1H 2021 Revenue1 Bridge by Product Line (€m) 30.7% 38.4% 56.8% 39.5% 35.4% 31.7% 16.6; 9% (€m) 9.1; 5% 88.4; 63.4; 50% 36% 2 Hip Knee Extremities Spine The good momentum of Hip was generated by the acquisition of new customers through the AMIS strategy supported by the roll-out of new products T
Slide 9: 1H 2021 Revenue Bridge by Geographic Area
1H 2021 Revenue1 Bridge by Geographic Area (€m) 29.4% 44.3% 33.6% 49.4% 35.4% 31.7% 5.7; 3% (€m) 43.0; 24% 76.2; 43% 52.5; 30% Europe NA APAC ROW In Europe, France, Italy and Belgium, the countries most affected by Covid-19 in 1H 2020, recorded the strongest growth, followed by the “DACH” countrie
Slide 10: P&L: Remarkable Profitability
1H 2021 P&L: Remarkable Profitability1 PROFIT & LOSS STATEMENT (€m) 1H 2020 A 1H 2021 A Revenues 134.8 177.5 Cost of Sales (40.9) (48.9) GROSS PROFIT 93.9 128.6 GROSS PROFIT MARGIN 69.7% 72.5% Research and Development expenses (3.3) (4.5) Sales and Marketing expenses (54.4) (61.0) General and Admini
Slide 11: Investments for Future Growth
1H 2021 Investments for Future Growth 1H 2021 Investments EUR 24.1m % of Revenues 13.6% (€m) Investments in instruments and in the Other development of new implants and Intangibles;3 surgical instruments to feed new 0.8; 3% customers started in 2021 and sustain the R&D growth Investments; Instrume
Slide 12: Positive Free Cash Flow Generation after Investments for Future Growth
1H 2021 Positive Free Cash Flow1 Generation after Investments for Future Growth ADJUSTED FREE CASH FLOW (€m) 1H 2020 A 1H 2021 A PROFIT FOR THE PERIOD 9.7 29.7 P&L Adjustments: Income tax expenses (0.4) 1.9 Depreciation and amortisation 18.8 18.5 Other P&L non-cash transactions 1.0 5.6 Movements in
Slide 13: Net Financial Debt: Strong Liquidity and Well Funded for Future Growth
Net Financial Debt: Strong Liquidity and Well Funded for Future Growth (€M) • Other includes Euro 2.9 million repayment lease liabilities, Euro 0.3 million purchase of treasure shares, Euro 2.5 million non cash transactions and Euro -0.3 million exchange rate effect. As part of the share purchase pl
Slide 14: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer 1H 2021 Financial Results
Slide 15: 2021 Outlook Confirmed
2021 Outlook Confirmed The second semester 2021 revenue growth is expected to normalize as the 2020 comparative period already benefited from previous pent-up demand in certain geographic areas We confirm our 2021 guidance of revenue, revised upward last July, within a range of Euro 355 million
Slide 16: Q&A
Q&A 1H 2021 Financial Results
Slide 17: Adedacta
Adedacta Adedacta International
Slide 18: Appendix
APPENDIX 1H 2021 Financial Results
Slide 19: Interim Consolidated Statement of Profit or Loss
Interim Consolidated Statement of Profit or Loss 19
Slide 20: Interim Consolidated Statement of Financial Position
Interim Consolidated Statement of Financial Position 20
Slide 21: Interim Consolidated Statement of Cash Flows
Interim Consolidated Statement of Cash Flows 21